Cybin (HELP) Income from Non-Controlling Interests (2020 - 2025)
Cybin's (HELP) quarterly Income from Non-Controlling Interests came in at $715.85 in Q4 2024, down 67.45% on a QoQ basis from $2199.2 in Q3 2024.
Cybin (HELP) Income from Non-Controlling Interests (2020 - 2025) Analysis & Trends
Cybin (HELP) has 4 years of Income from Non-Controlling Interests data on file, last reported at $715.85 in Q4 2024.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $715.85 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$1.7 million (changed N/A YoY) and the FY2021 annual result came in at $53757.5, changed N/A from the prior year.
- Income from Non-Controlling Interests slipped to $715.85 in Q4 2024, from $2199.2 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $25219.3 in Q2 2021 to a low of -$1.7 million in Q3 2022.
- A 4-year average of -$254386.7 and a median of $1442.4 in 2020 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2021 — Income from Non-Controlling Interests soared 1648.42% — and 2022, when it plunged 1000.81%.
- Tracing HELP's Income from Non-Controlling Interests over 4 years: stood at $1442.4 in 2020, then tumbled by 10564.29% to -$150937.8 in 2021, then sank by 1000.81% to -$1.7 million in 2022, then surged by 100.04% to $715.85 in 2024.
- The last three Income from Non-Controlling Interests figures came in at $715.85 (Q4 2024), $2199.2 (Q3 2024), and $2193.4 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -2.92 Mn |
| Dec 31, 2024 | 715.85 |
| Sep 30, 2024 | 2,199.16 |
| Jun 30, 2024 | 2,193.42 |
| Sep 30, 2022 | -1.66 Mn |
| Sep 30, 2021 | -150,937.77 |
| Jun 30, 2021 | 25,219.34 |
| Jun 30, 2020 | 1,442.41 |